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SHP-2 is a tyrosine phosphatase widely expressed and
involved in multiple cell signaling processes. Accumulating
evidence now is emerging whereby dysfunction in this
protein tyrosine phosphatase also represents a key factor in
the pathogenesis of gastrointestinal diseases, in particular in
chronic inﬂammation and cancer.
SHP-2 is a tyrosine phosphatase expressed in most embry-
onic and adult tissues. SHP-2 regulates many cellular func-
tions including growth, differentiation, migration, and
survival. Genetic and biochemical evidence show that SHP-2
is required for rat sarcoma viral oncogene/extracellular
signal-regulated kinases mitogen-activated protein kinase
pathway activation by most tyrosine kinase receptors, as
well as by G-protein–coupled and cytokine receptors. In
addition, SHP-2 can regulate the Janus kinase/signal trans-
ducers and activators of transcription, nuclear factor-kB,
phosphatidyl-inositol 3-kinase/Akt, RhoA, Hippo, andWnt/
b-catenin signaling pathways. Emerging evidence has shown
that SHP-2 dysfunction represents a key factor in the path-
ogenesis of gastrointestinal diseases, in particular in
chronic inﬂammation and cancer. Variationswithin the gene
locus encoding SHP-2 have been associated with increased
susceptibility to develop ulcerative colitis and gastric atro-
phy. Furthermore,micewith conditional deletionof SHP-2 in
intestinal epithelial cells rapidly develop severe colitis.
Similarly, hepatocyte-speciﬁc deletion of SHP-2 induces he-
patic inﬂammation, resulting in regenerative hyperplasia
and development of tumors in agedmice. However, the SHP-
2 gene initially was suggested to be a proto-oncogene
because activating mutations of this gene were found in
pediatric leukemias and certain forms of liver and colon
cancers. Moreover, SHP-2 expression is up-regulated in
gastric and hepatocellular cancers. Notably, SHP-2 functions
downstream of cytotoxin-associated antigen A (CagA), the
major virulence factor of Helicobacter pylori, and is associ-
ated with increased risks of gastric cancer. Further com-
pounding this complexity, most recent ﬁndings suggest that
SHP-2 also coordinates carbohydrate, lipid, and bile acid
synthesis in the liver and pancreas. This review aims to
summarize current knowledge and recent data regarding
the biological functions of SHP-2 in the gastrointestinal
tract. (Cell Mol Gastroenterol Hepatol 2016;2:11–21; http://
dx.doi.org/10.1016/j.jcmgh.2015.11.001)Keywords: PTPN11; inﬂammation; gastrointestinal cancer;
epithelium.
HP-2 is a SH2 domain-containing protein tyrosine
1–5Sphosphatase (PTP) encoded by the PTPN11 gene.
This PTP is expressed ubiquitously, sharing similar overall
structure and high homology with SHP-1 phosphatase,
which is expressed predominantly in hematopoietic cells.6
Both phosphatases contain 2 tandem SH2 domains at the
N-terminus and 1 tyrosine phosphatase domain at the
C-terminus (Figure 1). The SH2 domain is a sequence-
speciﬁc phosphotyrosine-binding motif that mediates sub-
strate recruitment and regulates phosphatase activity.7 In
its inactive state, the N-terminal SH2 domain of SHP-2 binds
the PTP domain, thus blocking access of substrates to the
active site. Upon binding to phosphoproteins, the SH2
domain is released from the PTP domain, enabling SHP-2 to
dephosphorylate its substrates.8,9 In addition, a new regu-
latory mechanism based on SHP-2 dimerization recently
was described. Indeed, 15% of SHP-2 in resting cells has
been found to be in dimeric form, resulting in a decrease in
catalytic activity of the phosphatase. Of note, the SH2
domains have no role in SHP-2 self-association.10 Impor-
tantly however, the dimer/monomer ratio is not static and
is regulated by growth factors and the cell redox state.10
Given the signiﬁcant regulatory role of SHP-2 in major
signaling pathways (described later), keeping SHP-2 activity
under control may be crucial for cell homeostasis.10
Previous biochemical evidence has shown that SHP-2
enzymatic activity is required for its function in signal
transduction.11–14 The replacement of cysteine 459 by
Figure 1. Structure of SHP-2. Deﬁned domains within SHP-
2 are indicated. SHP-2 contains 2 tandem SH2 domains
(blue), a single PTP domain (red), and a C-terminal hydro-
phobic tail that includes tyrosine phosphorylation sites
(green).
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to bind to other signaling intermediates via its SH2 domains.
This mutant thus functions as a dominant-negative molecule
over the endogenous wild-type SHP-2.15 By using this
Cys459Ser mutant, SHP-2 has been shown to positively
regulate the signaling pathways of insulin, epidermal
growth factor, platelet-derived growth factor, and ﬁbroblast
growth factor (FGF) in a number of studies, in both in vitro
and in vivo models. More speciﬁcally, the introduction of
this catalytically inactive SHP-2 mutant markedly inhibits
the activation of mitogen-activated protein kinases (MAPKs)
extracellular signal-regulated kinases (ERK)1/2 in response
to epidermal growth factor, insulin, thrombin, and
ﬁbronectin.12,14,16–20 Further genetic and biochemical evi-
dence also strongly shows that SHP-2 indeed is required for
ERK/MAPK pathway activation by most, if not all, tyrosine
kinase receptors, as well as by G-protein–coupled receptors,
cytokine receptors, and integrins.8,12,14,21,22 SHP-2 binds
directly to certain tyrosine kinase receptors or, more often,
to scaffolds (Table 1), leading to its activation. Cells
expressing dominant-negative SHP-214 or Ptpn11 gene exon
3–deleted mouse embryonic ﬁbroblasts22 show defective rat
sarcoma viral oncogene (RAS) activation, suggesting that
SHP-2 acts upstream of RAS (Figure 2). However, other
data have shown that a catalytically inactive mutant of
SHP-2 (Cys459Ser) can perturb components of downstream
signaling, even in the presence of a constitutively active RAS,
suggesting that SHP-2 also may function either downstream
and/or in parallel to RAS.13 In addition, SHP-2 was shown to
functionally regulate other pathways including the Janus
kinase/signal transducers and activators of transcrip-
tion,23,24 nuclear factor-kB (NF-kB),25,26 phosphatidyl-
inositol 3-kinase (PI3K)/Akt,27–29 Wnt/b-catenin,30,31
Hippo,31 and RhoA32,33 signaling (Figure 2).
Despite extensive studies over the past decade, the
mechanisms of SHP-2 action remain unclear. SHP-2 has been
reported to interact with a number of diverse signaling
components such as Gab1/2, ﬁbroblast growth factor re-
ceptor substrate, insulin receptor substrate 1/2, p85, STAT1/
3/5, Sprouty, and yes-associated protein/transcriptional
coactivator with PSD-95, discs large, zona occludens 1-
binding motif (Table 1 and Figure 2). As a result, SHP-2 has
been shown to regulate numerous cellular functions,
including progenitor cell development,34 growth,12,35 differ-
entiation,32,36 and migration.37,38 Notably, homozygous mice
carrying a targeted mutation in the murine Shp2 gene,
resulting in deletion of residues in the N-terminal SH2
domain, die around day 8.5–10.5 of gestation, with multiple
defects in mesodermal patterning.39PTPN11 Mutations and Phenotypes
In human beings, germline mutations in the Ptpn11 gene
(which encodes SHP-2) have been identiﬁed in more than
50% of children with Noonan syndrome, a developmental
disorder characterized by short stature, minor facial
anomalies, and congenital heart defects.40 Of note, most
children with Noonan syndrome show feeding and digestive
disorders including vomiting, constipation, abdominal pain,
and distension.41,42 Noonan syndrome also frequently is
associated with the development of juvenile myelomono-
cytic leukemia (JMML).40,43 Conversely, somatic mutations
in the PTPN11 gene also have been identiﬁed in 34% of
JMML patients. Most of these somatic mutations are clus-
tered within the PTP or the N-SH2 domain,44 altering the
autoinhibition mechanism and resulting in hyperactivated
SHP-2.43 Accordingly, expression of the most common and
most active PTPN11 mutation (E76K) found in JMML and
acute leukemias in pan hematopoietic cells in mice is suf-
ﬁcient to trigger the development of myeloproliferative
disorder. Subsequently, these mice progress to acute leu-
kemias.45 SHP-2 consequently has been identiﬁed as the
ﬁrst proto-oncogene to encode a tyrosine phosphatase.46
Accumulating evidence now is emerging whereby
dysfunction in this PTP also represents a key factor in the
pathogenesis of gastrointestinal (GI) diseases, in particular
in chronic inﬂammation and cancer. The following sections
provide an overview of current knowledge on the functions
and roles of SHP-2 in the epithelia of stomach, intestine,
pancreas, and liver.
SHP-2 in Gastric Carcinogenesis
A role for SHP-2 in gastric cancer was ﬁrst suggested in
2002 when it was found that this phosphatase is an intra-
cellular target of Helicobacter pylori cytotoxin-associated
gene A (CagA) protein.47 CagA is the product of the cagA
gene carried in virulent type I strains of H pylori, which in-
fects approximately half of the world’s population, causing
gastric diseases ranging from peptic ulcer diseases to gastric
adenocarcinoma.48,49 CagA is introduced into gastric epithe-
lial cells through a type IV secretion system and, once inside,
Src family kinases phosphorylate the Glu-Pro-Ile-Tyr-Ala
motif on tyrosine.50,51 Tyrosine-phosphorylated cagA then
speciﬁcally binds to the SH2 domains of SHP-2, relieving the
autoinhibition mechanism and thereby increasing its phos-
phatase activity,47 resulting in activation of the downstream
ERK/MAPK pathway.52 Activated ERK1/2 MAPK then pro-
motes proliferation and survival gene programs.53–55
Furthermore, infection of gastric epithelial cells with cagA-
positive H pylori has been shown to induce a unique elon-
gated cell shape termed the hummingbird phenotype, which is
dependent on cagA–SHP-2 interaction.47,52 These studies
hence provide a molecular basis for the pathogenic actions of
cagA on gastric epithelial cells.
STAT3 also is activated in patients with infection with
cagA-positive H pylori strains and with gastric adenocarci-
noma.56 Because SHP-2 is amajor negative regulator of STAT3
activation,23 sequestration or preferential binding by cagA
may reduce the intracellular pool of SHP-2, thereby depleting
Table 1.Binding Partners of SHP-2 in Gastrointestinal Cells
Organs Proteins Interactions Cell types Cell outcomes References
Stomach CagA SH2 domain of SHP-2
and phosphorylated
tyrosine in the EPIYA
motif of CagA
AGS cells
Human gastric
epithelial cells
Increased phosphatase activity of
SHP-2
Y
Induction of the hummingbird
phenotype
47, 59, 62, 117, 118
FAK SHP-2 in complex with
CagA and FAK
AGS cells Dephosphorylation of FAK on
Y397, Y576, and Y577 by
SHP-2
Y
Induction of the hummingbird
phenotype
119
gp130 SHP-2 in complex with
gp130
AGS cells Activation of ERK1/2 by gp130
Inhibition of the Jak2/STAT3
pathway by SHP-2
59
Paraﬁbromin SH2 domain of SHP-2
and paraﬁbromin
AGS cells Dephosphorylation of
paraﬁbromin on Y290, Y293,
and Y315 by SHP-2
Y
Interaction between
dephosphorylated
paraﬁbromin and b-catenin
Y
Nuclear accumulation of
b-catenin and transcription of
Wnt/b-catenin target genes
30
YAP and TAZ C-terminal tail of SHP-2
and WW domain and
C-terminus PDZ-
binding motif of TAZ
AGS cells Dephosphorylation of YAP/TAZ
by SHP-2
Y
Nuclear accumulation of SHP-2
Y
Interaction between
dephosphorylated
paraﬁbromin
Y
Transcription of TEAD-regulated
genes
31
Intestine IL22R1 SHP-2 and
phosphorylated
IL22R1 (Y251, Y301)
SW480 cells Activation of the ERK1/2 and Jak/
STAT3 signaling pathways by
IL22
120
Bgp1 N-SH2 domain of SHP-2
and phosphorylated Y
in the ITIM motif of
Bgp1
CT51 cells ND 121
Liver FRS2a SH2 domain of SHP-2
and phosphorylated Y
of FRS2a
Hep3B cells
Mouse hepatic cells
Activation of the ERK1/2 pathway
by FGFR4
105
Gab1 SH2 domain of SHP-2
and phosphorylated Y
of Gab1
Hep3B cells
Hep2G cells
Mouse hepatic cells
Activation of the ERK1/2 pathway 90, 105, 122
Liver and
pancreas
COP1
FASN
N-SH2 domain of SHP-2
in a complex,
association with
FASN and COP1
Mouse hepatic cells
Mouse pancreatic cells
FASN ubiquitination and
degradation
Y
Impact on lipid metabolism and
glucose homeostasis
101
January 2016 Roles of SHP–2 Phosphatase in the GI Tract 13this brake on STAT3 activation and resulting in increased
transcription of STAT3 target genes, many of which promote
proliferation, inﬂammation, angiogenesis, and inhibition of
apoptosis.56–58 In addition, cagA may interact directly with
STAT3bybinding or recruitment to gp130, therebypromoting
hyperactivation and increased transcriptional activity.59 Ofnote, the STAT3, butnot theERK1/2, pathwaycanbe activated
to a lesser extent by cagA-negativeH pylori strains, suggesting
that STAT3 may be driven by other bacterial factors. The dif-
ferential activationof these 2 signalingproteinsmayexplain in
part the increased predisposition of gastric epithelium to
gastric cancer when infected with cagAþ H pylori strains
Table 1.Continued
Organs Proteins Interactions Cell types Cell outcomes References
Pancreas p85/PI3K
IRS2
SHP-2 in a complex with
p85 and IRS2
INS-1 832/13
pancreatic cells
Glucose-induced activation of the
Akt/FoxO1 pathway
Y
Insulin production
98
Sprouty 1 ND INS-1 832/13
cells
Dephosphorylation of Sprouty 1
on Y by SHP-2
Y
Glucose-induced activation of the
ERK1/2 pathway
Y
Insulin production
98
AGS, human gastric carcinoma cells; Bgp1, biliary glycoprotein 1; COP1, constitutive photomorphogenesis protein 1; CT51,
mouse colonic carcinoma cells; EPIYA, Glu-Pro-Ile-Tyr-Ala; FAK, focal adhesion kinase; FASN, fatty acid synthase; FRS2a,
ﬁbroblast growth factor receptor substrate 2 a; Gab1, Grb2-associated binding protein; Hep, human hepatocellular carcinoma
cells; IL22R1, interleukin-22 receptor 1; INS-1 832/13 cells, insulin-producing b-cells; IRS2, insulin receptor substrate 2; ITIM,
immunoreceptor tyrosine-based inhibitor motif; ND, not determined; SW480, human colonic adenocarcinoma cells; TAZ,
transcriptional coactivator with PDZ-binding motif; Y, tyrosine; gp130, glycoprotein 130; YAP, yes-associated protein.
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because SHP-2, STAT3, and ERK1/2MAPK are components of
intracellular signaling of both growth factors and cytokines, it
is likely that inappropriate activation of these proteins also
may occur in gastric tumors, independently of infection.56
Of particular interest, transgenic mice expressing wild-
type cagA show gastric epithelial hyperplasia, with some
of the mice developing gastric polyps and adenocarcinoma.
By contrast, these pathologic abnormalities are not
observed in transgenic mice expressing the
phosphorylation-resistant cagA, which is unable to bind
SHP-2.61 These ﬁndings thus highlight the importance of
cagA tyrosine phosphorylation, which enables cagA to
deregulate SHP-2 in the development of H pylori–associated
neoplasms. Of note, in vivo interaction between cagA and
SHP-2 has been observed in patients with atrophic gastritis,
but not in patients with intestinal metaplasia or cancer,
suggesting that this mechanism is critical in the early phases
of human gastric carcinogenesis.62
Different cagA types have been studied in relation to
gastric cancer incidence. CagA-positive strains can be
divided into East Asian and Western types based on dif-
ferences in the sequences in the 30 region of cagA,63 which
contains a different number of copies of the Glu-Pro-Ile-Tyr-
Ala tyrosine phosphorylation site motif. In particular, pa-
tients infected with the East Asian cagA-positive strains
present higher disease severity compared with patients
infected with the Western cagA-positive strains, the former
being correlated with stronger SHP-2-binding activity.64
Of note, single-nucleotide polymorphisms in the PTPN11
gene have been associated with gastric atrophy in both
Japanese (rs2301756)65,66 and Chinese (rs12229892 and
rs12423190)67,68 populations. Although the impact of these
polymorphisms currently is unknown, one could speculate
that they may affect SHP-2 expression or activity or the
interaction between cagA and SHP-2. Further studies in
human specimens are needed to verify this hypothesis.Interestingly, SHP-2 is overexpressed in gastric carci-
nomas but independently of H pylori infection.69–71 This
suggests that SHP-2 could be modulated by different onco-
genic pathways, emphasizing that this phosphatase may be
crucial for gastric tumorigenesis. Although the precise mech-
anisms underlying the effect of SHP-2 on gastric carcinogen-
esis remain to be investigated further, targeting SHP-2 may
represent a novel therapeutic approach for gastric cancer.
SHP-2 in Intestinal Inﬂammatory
Bowel Diseases
A major advancement in understanding some of the
in vivo functions of SHP-2 in the intestine recently was
achieved by using conditional tissue-speciﬁc disruption of
SHP-2 in mice (SHP-2intestinal epithelial cell (IEC)-knockout (KO)
mice). Our group generated a mouse model with impaired
SHP-2 expression by using the villin promoter villin-Cre,
which ablates the ﬂoxed gene from all epithelial cells
(including stem cells) of the small intestine and colon, but
not in the mesenchymal compartment.72 Importantly, these
mice rapidly develop severe inﬂammation 1 month after
birth, with clinical and histopathologic features similar to
ulcerative colitis.73 Two further studies also have reported
that mice featuring a villinCre-mediated SHP-2 deletion
rapidly develop colitis.74,75 These ﬁndings thus clearly
establish intestinal epithelial SHP-2 as a critical determinant
for prevention of inﬂammation in the colon.
Of particular interest, intestinal permeability is increased
markedly in mice with IEC-speciﬁc deletion of SHP-2.73
Furthermore, SHP-2IEC-KO mice feature reduced Goblet cell
numbers associated with expansion of Paneth cells and
increased lysozyme expression in their small intestine.74
These data hence suggest that SHP-2–dependent signaling
directs cells to the Goblet cell fate while preventing Paneth
cell expansion.74 Dysregulation of epithelial cell fate or dif-
ferentiation, particularly in the colon, may have deleterious
A B C
D E
Figure 2. Signaling pathways regulated by SHP-2 in the gastrointestinal tract. (A) In response to growth factors, SHP-2
binds via its SH2 domains either to autophosphorylated receptors (such as that for platelet-derived growth factor, not
shown) or to docking proteins (such as the Grb2-associated proteins Gabs and ﬁbroblast growth factor receptor substrate
[FRS2]), which are tyrosine-phosphorylated by activated receptor tyrosine kinases or by Src family kinases. Such interactions
result in the activation of SHP-2 and its consequent promotion of Ras activation, leading to cell growth. (B) In response to
cytokines, the Janus kinases become phosphorylated and then phosphorylate STAT transcription factors, which dimerize and
enter the nucleus. SHP-2 can inhibit this process by directly dephosphorylating either the Janus kinases or STAT proteins. (C)
In response to insulin, SHP-2 assembles in a complex with insulin-receptor substrate (IRS)1/2 and the p85 subunit of PI3K,
leading to Akt activation, leading to cell survival. (D) During H pylori infection, cagA is injected into the gastric epithelial cells
and is phosphorylated by Src family kinases. SHP-2 then interacts with phosphorylated cagA, leading to the activation of the
ERK1/2 MAPK pathway in a Ras-independent manner and to focal adhesion kinase (FAK) dephosphorylation and inactivation.
CagA also can interact directly with STAT3 by binding or recruitment to gp130, thereby promoting hyperactivation and
increased transcriptional activity. (E) At low cell density, nonphosphorylated YAP/TAZ promotes nuclear translocation of SHP-
2, which in turn stimulates T-cell factor/lymphoid enhancer factor- and TEA domain family members-regulated genes via
paraﬁbromin dephosphorylation.
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2–deﬁcient mice that rapidly develop severe colitis.76
Conversely, Paneth cells that produce antimicrobial pep-
tides such as a- and b-defensins and lysozyme also
may participate in the development of colitis in SHP-2IEC-KO
mice. Indeed, antimicrobial proteins shape the compositionand abundance of microbiota, and segregate intestinal
commensals from the mucosa.77,78 Hence, one could spec-
ulate that loss of epithelial SHP-2 expression has a signiﬁ-
cant effect on key gut microbial groups that are important
for homeostasis. Of note, the beneﬁcial effect of antibiotics
observed in the SHP-2IEC-KO mouse model73 suggest a role
16 Coulombe and Rivard Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 1for microﬂora in the initiation of inﬂammation. In this
respect, both clinical observations and animal studies sup-
port the involvement of intestinal microﬂora in the patho-
genesis of inﬂammatory bowel diseases (IBDs).73 It
therefore is tempting to speculate that a distinctive micro-
biota composition and a reduced functionality of the mucus
barrier observed early in SHP-2–deﬁcient mice are at the
source of this inﬂammation.
Exactly how SHP-2 impacts cell fate is not totally clear
but may rely on its ability to activate the Raf/MAPK
pathway. Indeed, concomitant expression of activated
KRas75 or MEK174 markedly promotes Goblet cell differen-
tiation in the colon of SHP-2IEC-KO mice and prevents the
development of colitis. In fact, Heuberger et al74 recently
reported that SHP-2–dependent ERK signaling controls the
choice between Goblet and Paneth cell fate in the small in-
testine. These investigators showed that inhibition of ERK
signaling in small intestinal organoids and cultured cells
promotes b-catenin transcriptional activity, which in turn
induces a Paneth-cell maturation program.79 Taken
together, these studies suggest that SHP-2–dependent ERK
signaling directs Goblet cell differentiation after secretory
progenitor speciﬁcation, at the expense of Paneth cell dif-
ferentiation in the intestine.
Importantly, intronic polymorphisms in the PTPN11
gene encoding for SHP-2 have notably been described in
Japanese patients with ulcerative colitis.80 However, the
impact of these polymorphisms on SHP-2 function was not
elucidated. These investigators speculated that PTPN11
polymorphisms may affect the expression, activity, or af-
ﬁnity of SHP-2 to immunoreceptors in T and B cells.
Accordingly, we found reduced SHP-2 gene transcripts in
intestinal biopsy specimens from patients with active ul-
cerative colitis, emphasizing the inverse relationship be-
tween SHP-2 expression and colonic inﬂammatory
phenotype.73 This could suggest that PTPN11 SNPs affect
SHP-2 expression. However, additional biochemical and
molecular studies conducted in a large number of human
specimens are needed to verify this hypothesis.
Overall, these ﬁndings show that SHP-2 is required for
homeostasis of the intestinal epithelium, in particular for
proper differentiation of secretory progenitors. The next
step will be to elucidate the exact molecular mechanisms by
which SHP-2 exerts such protective effects on intestinal
barrier function. Given that IBDs are very complex diseases,
the identiﬁcation of the speciﬁc SHP-2 targets may be one
additional step in understanding the heterogeneity of these
diseases.SHP-2 in Colorectal Cancer
Recent data from our laboratory have shown that IEC-
speciﬁc deletion of SHP-2 promotes chronic inﬂammation
in the colon that results in regenerative hyperplasia and
development of adenocarcinomas in aged mice (Gagné-
Sansfaçon et al, unpublished data). These ﬁndings are
reminiscent of those observed by Bard-Chapeau et al,81 who
recently reported that hepatocyte-speciﬁc deletion of SHP-2
also promoted inﬂammation and tumorigenesis in the liverof aged mice. Over the past decade, many studies have
linked chronic inﬂammation to cancer development,
particularly in the GI tract (recently reviewed by Fichtner-
Feigl et al,82 2015). For instance, chronic intestinal inﬂam-
mation has been shown to support tumor initiation through
oxidative stress–induced mutations.83 Therefore, these re-
sults suggest that by suppressing inﬂammation, SHP-2
prevents the development of tumors in the colon and the
liver (see later for further discussion regarding the liver).
Accordingly, SHP-2 levels are decreased signiﬁcantly in
colitis-associated tumors in mice.84 Likewise, in colorectal
carcinomas, SHP-2 has been reported to be down-regulated
at both the messenger RNA and protein levels, with lower
SHP-2 expression being correlated with advanced
stages.84,85 In keeping with this, higher expression of SHP-2
in colorectal cancer patients has been related to better
survival.86 Thus, these ﬁndings support the concept that,
under speciﬁc contexts (such as inﬂammation), SHP-2 can
act as a tumor suppressor.
Paradoxically, however, in human beings, gain-of-
function mutations in the PTPN11 gene (SHP-2 gene) pre-
viously associated with certain forms of leukemias have
been found in certain solid carcinomas including colorectal
cancers.44 The somatic mutation speciﬁcally found in colo-
rectal cancer specimens, the E76G mutation, disrupts the
inhibitory intramolecular interaction with the PTP domain
and leads to the hyperactivation of SHP-2.44 Mutations of
this residue commonly are found in JMML.43,44 In addition,
in JMML, SHP-2 mutations are mutually exclusive with RAS
or NF1 (a negative regulator of Ras), and several ﬁndings
indicate that SHP-2 contributes to leukemia carcinogenesis
through Ras activation.87 Of note, in colorectal cancer, KRAS
or NRAS are mutated in nearly 50% of colorectal tumors at a
relatively early stage of the carcinogenic process.88,89 It
therefore remains possible that the SHP-2 E76G mutation
and/or SHP-2 overexpression/activation, by inducing the
Ras/ERK signaling pathway, may be involved in early al-
terations leading to tumor formation in the colon in a spo-
radic context. It will be pertinent in future studies to
determine whether gain-of-function mutations or over-
expression of SHP-2 in intestinal epithelial cells also can
cause or enhance colorectal tumorigenesis.SHP-2 in Liver Inﬂammation and Cancer
A study conducted in hepatocyte-speciﬁc SHP-2
knocked-out mice has shown that SHP-2 ablation attenuates
hepatocyte proliferation and liver regeneration after partial
hepatectomy.90 However, these mice also develop hepatic
inﬂammation and necrosis and, with age, develop hepato-
cellular adenomas. Moreover, hepatocyte-speciﬁc ablation of
SHP-2 also drastically enhances liver tumor development in
mice after injection of the chemical carcinogen diethylni-
trosamine, reinforcing the tumor-suppressing function of
SHP-2 in the liver.81 In keeping with these results, decreased
SHP-2 expression has been detected in some human hepa-
tocellular carcinoma (HCC) patient samples.81,91,92 Howev-
er, SHP-2 expression recently was examined extensively in a
large number of human HCCs and in which SHP-2
January 2016 Roles of SHP–2 Phosphatase in the GI Tract 17transcripts were signiﬁcantly lower in 22% of HCCs relative
to the paired noncancerous tissues, although higher SHP-2
expression surprisingly was found in 78% of HCCs.93
Immunoblot and immunostaining analyses also showed
SHP-2 up-regulation in a majority of HCCs. Of particular
note, SHP-2 expression was increased signiﬁcantly in met-
astatic foci compared with the matched primary HCCs or
adjacent normal tissues, thus indicating a potential role of
SHP-2 in HCC metastasis. In addition, SHP-2 silencing in
hepatoma cells suppressed their proliferation as well as
their tumorigenic and invasive/metastatic potential,
possibly by reducing the activation of RAS/ERK and PI3K/
Akt signaling.93
Altogether, these data suggest that SHP-2 displays dual
facets in liver cancer, either suppressing or promoting HCC
development.93,94 Such a dual signaling role shown by a
single protein in tumorigenesis is not without precedent. NF-
kB,95 STAT3,96 JNK,97 and paraﬁbromin30 also can function as
tumor suppressors or oncoproteins in a cell con-
text–dependent manner. One could speculate that different
binding partner proteins may direct the opposing cellular
responses under physiological and pathologic conditions.SHP-2 in Lipid and Glucose Metabolism
Accumulating evidence from mouse models has indicated
that SHP-2 regulates glucose and lipid metabolism. For
instance, Shp-2 deletion in the pancreas in mice causes
defective glucose-stimulated insulin secretion and impaired
glucose tolerance.98 In effect, Shp-2 deﬁciency impairs the
expression of Pdx1 and insulin genes, leading to reduced in-
sulin production by b-cells.98 On the other hand, mice lacking
Shp-2 in the liver show increased hepatic insulin action and
glucose tolerance, as well as enhanced systemic insulin
sensitivity comparedwith control mice, indicating that SHP-2
is a negative regulator of insulin signaling in hepatocytes.
Acute SHP-2 deletion by tail-vein injection of adenovirus-
carrying Ad5-Cre in SHP-2ﬂox/ﬂox mice yields comparable
results.99 SHP-2 has been proposed to putatively regulate
liver insulin signaling by inhibiting insulin-receptor sub-
strate 1/2 tyrosine phosphorylation, thereby attenuating
PI3K association and Akt activation.99 Of note, SHP-2 protein
expression in hepatocytes is regulated by nutritional status,
increasing in mice fed a high-fat diet and decreasing during
fasting.100 Thus, when challenged with high-fat feeding, mice
with hepatic SHP-2 deﬁciency gain less weight and show
decreased liver steatosis in comparison with control mice. In
addition, hepatic SHP-2 deﬁciency attenuates the develop-
ment of high-fat-diet–induced insulin resistance.
Lastly, in addition to the earlier-described observations,
SHP-2 has been shown to regulate the degradation of fatty
acid synthase, a key enzyme in fatty acid biosynthesis.
Indeed, SHP-2 interacts with fatty acid synthase and induces
its ubiquitination and degradation by forming a complex
with ubiquitin E3 ligase COP1 and p38 MAPK. Accordingly,
increased FAS protein levels have been observed in the liver
and pancreas of SHP-2 conditional knocked-out mice.101
Studies in the past decade have provided evidence that
bile acids are not simply biological detergents facilitatinglipid absorption, but also key metabolic regulators of
glucose and lipid homeostasis.102,103 Interestingly, a novel
function of SHP-2 in control of bile acid homeostasis has
been found. Indeed, hepatocyte-speciﬁc deletion of SHP-2
results in bile acid accumulation and an enlarged bile acid
pool in the liver. When fed a chow diet, these mice develop
liver injury consistent with bile acid–induced damage to the
hepatobiliary system.104 These phenotypic alterations can
be explained by the fact that SHP-2 is required for FGF15/
19 activation of FGFR4 and its downstream signaling path-
ways that repress bile acid biosynthesis in hepatocytes.105
Collectively, these studies indicate that hepatic SHP-2 is
involved in the regulation of lipid and glucose metabolism,
as well as in systemic energy balance.Conclusion and Perspectives
Genome-wide association studies have associated the
PTPN11 gene with gastric atrophy,67 gastric cancer,66 colitis,
and serum lipid levels.106,107 The mechanisms underlying
these associations are still in the hypothesis stage, which
stipulates that PTPN11 SNPs may change the expression of
the gene and consequently inﬂuence the SHP-2 protein,
which in turn regulates proliferation, differentiation, and/or
metabolism in the cells. Conversely, somatic gain-of-function
mutations in PTPN11 have been detected in colorectal
cancer.44 Hence, these genetic alterations strongly suggest
that SHP-2 may play a prominent role in various functions
of the GI system. Accordingly, anti-inﬂammatory and anti-
tumoral actions of SHP-2 furthermore have been shown
with the generation of hepatocyte and intestinal epithelial
cell–speciﬁc SHP-2– deﬁcient mice.73,81 The exact mecha-
nism by which SHP-2 ablation in colonocytes and hepato-
cytes induces such effects is not totally clear. Notably,
although the ERK pathway consistently was inhibited in
colonocytes73 and hepatocytes81 of these mice, NF-kB and
STAT3 conversely were hyperactivated. Importantly, both of
these transcription factors have been identiﬁed as impor-
tant contributors to inﬂammation-associated tumor devel-
opment.108–110 Previous studies furthermore have
documented a negative regulatory role of SHP-2 in the Janus
kinase/signal transducers and activators of transcrip-
tion23,81 and NF-kB signaling.26 However, the context in
which these major proinﬂammatory pathways speciﬁcally
are regulated by SHP-2 remains unknown. Interestingly,
IECs and hepatocytes have been found to be hypersensitive
to lipopolysaccharide challenge (increased NF-kB activation
and chemokine/cytokine production) after SHP-2
silencing.81 Hence, one could speculate that the phospha-
tase SHP-2 protects epithelial cells from aberrant Toll-like
receptor signaling, which can lead to uncontrolled inﬂam-
mation detrimental to the host. Abundant evidence also
supports the pivotal role of pattern-recognition receptors
including Toll-like receptors in gastric, intestinal, and liver
carcinogenesis.111–115 Further study in this area nonetheless
is needed to elucidate whether SHP-2 limits the innate im-
mune response in gastrointestinal tract epithelia.
Lastly, nothing is known regarding the regulation of SHP-
2 phosphatase activity in IBD or other gastrointestinal
18 Coulombe and Rivard Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 1diseases. SHP-2 is inactivated during oxidative stress and in
the presence of nitric oxide by-products.116 This suggests
that loss of SHP-2 activity and of the cellular pathways
regulated by SHP-2 may coincide with cell injury and
oxidative stress occurring during inﬂammation.82 Fully
characterizing not only the downstream effectors but also
the upstream regulators of SHP-2 phosphatase will provide
further insights in explaining the mechanistic link between
inﬂammation and GI cancers.References
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